In Brief: Juvenile rheumatoid arthritis
Executive Summary
Juvenile rheumatoid arthritis: FDA's Arthritis Advisory Committee is scheduled to meet July 23 to discuss a subpart of the guidance document for developing clinical programs for drugs, devices and biologics for treatment of RA. The workshop will be held at the Holiday Inn, Bethesda, Md. beginning at 8 a.m. FDA most recently held a workshop on RA and remission claims on March 27 ("The Pink Sheet" April 8, p. 16)...